Marco Gizzi

Grand Rue 3
Charleroi, WAL 6000, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Early Intermittent Cabozantinib in Metastatic Renal Cell Carcinoma: Efficacy and Safety in a Multicenter Retrospective Analysis.

Early Intermittent Cabozantinib in Metastatic Renal Cell Carcinoma: Efficacy and Safety in a Multicenter Retrospective Analysis.

Journal: Clinical genitourinary cancer

Published: April 22, 2026

Systemic Treatments for Metastatic Prostate Cancer in 2024.

Systemic Treatments for Metastatic Prostate Cancer in 2024.

Journal: European urology focus

Published: May 28, 2024

Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study.

Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study.

Journal: BMC cancer

Published: October 06, 2020

Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).

Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).

Journal: BMC cancer

Published: September 30, 2020

Rhabdomyolysis and acute kidney injury induced by the association of rosuvastatin and abiraterone: A case report and review of the literature.

Rhabdomyolysis and acute kidney injury induced by the association of rosuvastatin and abiraterone: A case report and review of the literature.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: May 14, 2020

Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy.

Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 28, 2019

Advancing therapies in metastatic castration-resistant prostate cancer.

Advancing therapies in metastatic castration-resistant prostate cancer.

Journal: Expert opinion on pharmacotherapy

Published: October 13, 2018

Corrigendum to "Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours" [Eur J Cancer 69 (2016) 151-157].

Corrigendum to "Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours" [Eur J Cancer 69 (2016) 151-157].

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 12, 2017

Atezolizumab (Tecentriq®): Activity, indication and modality of use in advanced or metastatic urinary bladder carcinoma

Atezolizumab (Tecentriq®): Activity, indication and modality of use in advanced or metastatic urinary bladder carcinoma

Journal: Bulletin du cancer

Published: February 22, 2017

Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours.

Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 28, 2016

Axitinib in metastatic renal cell carcinoma.

Axitinib in metastatic renal cell carcinoma.

Journal: Expert review of anticancer therapy

Published: April 25, 2015

Late recurrent testicular seminoma: histological evidence is required.

Late recurrent testicular seminoma: histological evidence is required.

Journal: Oncology research and treatment

Published: February 02, 2015

Showing 1-12 of 16

Last Updated: 09/26/2026